Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, and ...
The "Growth Opportunities in Emerging Nutricosmetics Technologies, 2024-2029" report has been added to ResearchAndMarkets.com's offering.Consumer awareness regarding skin health and how to achieve it ...
The FDA approval of Otulfi™, Fresenius Kabi’s fourth biosimilar product in the U.S. market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. and ...
Compared to traditional cocoa bean production, growing it in a lab allows for greater control over the final product, according to Beressi Golomb. “We’re combining biotech, agritech and AI to create ...
BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that the U.S. Food and Drug Administration (FDA) ...